Abstracts Archive - Page 2327 of 2607 - ACR Meeting Abstracts

Abstract Number: 1595 • 2013 ACR/ARHP Annual Meeting
Electroclinical Correlates and Outcome Of Status Epilepticus In Systemic Lupus Erythematosus
Jamal Mikdashi¹, Tricia Ting² and Allan Krumholz³, ¹Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, ²Neurology, University of Maryland. School of Medicine, Baltimore, MD, ³Neurology, University fo Maryland school of Medicine, Baltimore, MD
Background/Purpose: Predictors of seizures and epilepsy in systemic lupus erythematosus (SLE) patients are well described but descriptions of status epilepticus (SE) have thus far been…
Abstract Number: 1598 • 2013 ACR/ARHP Annual Meeting
Cognitive Dysfunction, a Non-Inflammatory Neuropsychiatric Syndrome In Systemic Lypus Erythematosus
Juanita Romero-Díaz¹, Alí Duarte-García², Sandra Juarez-Arellano³, Alba Cicero-Casarrubias¹, Hilda Fragoso-Loyo⁴, Luis Llorente⁵ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Medicine, Tufts Medical Center, Boston, MA, ³Department of Neurology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁵Immunology and Rheumatology Department, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Cognitive dysfunction (CD) affects 15 – 60% of SLE patients; nevertheless, its pathogenesis and predisposing factors are unknown. Objective: To identify factors associated with CD…
Abstract Number: 1599 • 2013 ACR/ARHP Annual Meeting
High Proportion Of Intrathecal Ro52 SSA Antibodies In Neuropsychiatric Lupus Patients – Relations To Neuropsychiatric Manifestations
Johanna Estelius¹, Liisa Hopia², Vijole Dzikaite-Ottosson³, Magnus LA. Andersson⁴, Elisabet Svenungsson⁵ and Jon Lampa⁶, ¹Department of Medicine, Rheumatology Unit, Center for Molecular medicine (CMM), Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Centre for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden, ⁴Department of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ⁶Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Neuropsychiatric (NP) manifestations in Systemic Lupus Erythematosus (SLE) are often associated with significant impact on quality of life and work capability. The underlying mechanisms…
Abstract Number: 1600 • 2013 ACR/ARHP Annual Meeting
Anti-Ribosomal P Protein Antibodies Exacerbate Long-Term Prognosis In Patients With Diffuse Neuropsychiatric/Neuropsychological Syndromes In Systemic Lupus Erythematous
Yoshiyuki Arinuma¹, Hirotoshi Kikuchi², Eisuke Ogawa¹, Tatsuhiko Wada¹, Tatsuo Nagai³, Sumiaki Tanaka¹ and Shunsei Hirohata¹, ¹Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Systemic lupus erythematous (SLE) is a chronic inflammatory disease characterized by the expression of a variety of autoantibodies. Although the comprehensive survival from the…
Abstract Number: 1601 • 2013 ACR/ARHP Annual Meeting
The Presence Of IgG-Immune Complexes In The Cerebrospinal Fluids Is Associated With Central Neurocychiatric Manifestatin But Not With Intrathecal Production Of Proimmflammatory Cytokines/Chemokines Such as Interferon-α In Systemic Lupus Erythematosus
Taku Yoshio¹, Hiroshi Okamoto², Kazuhiro Kurasawa³, Yoshiaki Dei⁴, Shunsei Hirohata⁵ and Seiji Minota⁶, ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, ²Minami-Otsuka Institute of Thechnology, Minami-Otsuka Clinic, Tokyo, Japan, ³Clinical Immunology, Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi-ken, Japan, ⁴Saiseikai Utsunomiya Hospital, Utsunomiya-shi, Tochigi-ken, Japan, ⁵Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ⁶Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan
Background/Purpose: IgG-Immune complexes (IC) formed by CSF autoantibodies in patients with neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE) has reported to stimulate the production of…
Abstract Number: 1602 • 2013 ACR/ARHP Annual Meeting
Autoantibodies, Cytokines and Chemokines In Serum and Cerebrospinal Fluid Of SLE Patients With Cognitive Dysfunction
Hilda Fragoso-Loyo¹, Alí Duarte-García², Sandra Juárez-Arellano³, Alba Cicero-Casarrubias⁴, Juanita Romero-Díaz⁵, Luis LLorente-Peters¹ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ²Department of Medicine, Tufts Medical Center, Boston, MA, ³Department of Neurology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: The nature and pathogenesis and cognitive dysfunction (CD) in patients with SLE is unkown.To determine the presence and levels of autoantibodies, cytokines and chemokines…
Abstract Number: 1561 • 2013 ACR/ARHP Annual Meeting
Treat-To-Target In Systemic Lupus Erythematosus: Report From the T2T/SLE Working Party
Ronald F. van Vollenhoven¹, Marta Mosca², George Bertsias³, Annegret Kuhn⁴, Kirsten Lerstrøm⁵, Josef S. Smolen⁶, David A. Isenberg⁷, Matthias Schneider⁸ and the T2T/SLE Working Party⁹, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²I, Rheumatology Unit, Internal Medicine, University of Pisa, Pisa, Italy, ³Rheumatology, Clinical Immunology, and Allergy, University of Crete, Heraklion, Greece, ⁴University of Münster, Münster, Germany, ⁵Lupus Europe, Farum, Denmark, ⁶Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁷Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁸Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ⁹the Karolinska Institute, Stockholm, Sweden
Background/Purpose: The principle of treating-to-target has been applied successfully to many diseases outside rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic targets and…
Abstract Number: 1562 • 2013 ACR/ARHP Annual Meeting
Elevated Serum B-Cell Activating Factor (BAFF/BlyS) Characterises Disease Relapse Following Rituximab In Systemic Lupus Erythematosus
Lucy M. Carter¹, David A. Isenberg² and Michael R. Ehrenstein³, ¹University College London, London, United Kingdom, ²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Numerous reports suggest that B cell depletion therapy (BCDT) using rituximab is effective in patients with systemic lupus erythematosus (SLE). However, two major trials…
Abstract Number: 1564 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Influenza Vaccination Is Strongly Decreased In Systemic Lupus Erythematosus: A Meta-Analysis Of Literature Data
Laurent Arnaud¹, Alexis Mathian², Hervé Devilliers³, Du Boutin-LE Thi Huong⁴, Ahlem Chaib⁴, Fleur Cohen-Aubart⁴, Julien Haroche¹, Miguel Hié⁴, Makoto Miyara⁴ and Zahir Amoura⁴, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, ⁴Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: Several studies suggest that the efficacy of influenza vaccination may be decreased in systemic lupus erythematosus (SLE). We performed a meta-analysis to assess systematically…
Abstract Number: 1565 • 2013 ACR/ARHP Annual Meeting
RNA-Sequencing Confirms Clinical Safety Of Herpes Zoster Vaccine
Christopher J. Lessard^1,2, Indra Adrianto³, Joel M. Guthridge⁴, John A. Ice³, Graham B. Wiley³, Stuart B. Glenn³, Judith A. James^1,2, Joan T. Merrill¹, Patrick M. Gaffney¹, Courtney G. Montgomery³, Kathy L. Sivils^1,5 and Eliza Chakravarty³, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE patients have increased risk of Herpes Zoster (HZ). A live-attenuated vaccine is available for healthy persons > 50 years old, but its safety…
Abstract Number: 1566 • 2013 ACR/ARHP Annual Meeting
Consensus Definition and Preliminary Validation Of a Low Disease Activity State In Systemic Lupus Erythematosus
Eric F. Morand¹, Kate Franklyn¹, Chak S. Lau², Sandra V. Navarra³, Worawit Louthrenoo⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Singgih Wahono⁷, Shun-Le Chen⁸, Jinou Ou⁹, Alberta Y. Hoi¹ and Mandana Nikpour¹⁰, ¹Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³University of Santo Tomas Hospital, Manila, Philippines, ⁴Dept of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁶Hasan Sadikin Hospital, Bandung, Indonesia, ⁷Universitas Brawijaya, Malang, Indonesia, ⁸Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁹3rd Hospital of Sun Yat-san University, Guang Zhou, China, ¹⁰Department of Medicine (St Vincent's Hospital), University of Melbourne, Fitzroy, Australia
Background/Purpose: The definitions of low disease activity state (LDAS) and remission as desirable treatment goals in rheumatoid arthritis have been widely applied in research and…
Abstract Number: 1567 • 2013 ACR/ARHP Annual Meeting
Desensitization To Trimethoprim/Sulfamethoxazole In Systemic Lupus Erythematosus Patients : A Retrospective Cohort Study
Yasuhiro Suyama¹, Mitsumasa Kishimoto¹, Hiroto Nakano², Chisun Min³, Yoichiro Haji¹, Ryo Rokutanda¹, Yuri Ohara¹, Hisanori Shimizu¹, Ken-ichi Yamaguchi⁴, Yukio Matsui⁴, Kazuo Matsui² and Masato Okada⁴, ¹Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ³Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁴Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: A high incidence of trimethoprin-sulfamethoxazole (TMP/SMX) hypersensitivity is reported in patients with systemic lupus erythematosus (SLE), and reactions are often severe. Desensitization protocol is…
Abstract Number: 1568 • 2013 ACR/ARHP Annual Meeting
A Comparative Study For High Prevalence Of A Positive Family History Of Systemic LUPUS Erythematosus In Juvenile-Onset Systemic LUPUS Erythematosus Versus Adult-Onset Disease
Maumer Durrani¹, Shirish Sangle¹, Natasha Jordan² and David P. D'Cruz¹, ¹Louise Coote Lupus Unit, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, ²Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom
Background/Purpose: The pathogenesis of SLE is complex and poorly understood. Infectious triggers, immunological abnormalities, environmental factors and genetic background play a combined role in disease…
Abstract Number: 1569 • 2013 ACR/ARHP Annual Meeting
The Accuracy Of The ICD-9 Code 710.0 To Identify a Cohort Of SLE Patients From The Electronic Medical Record
Arshad Mustafa¹, Jennifer Cai², Teresa Bosler², Nancy J. Olsen³ and David R. Karp¹, ¹Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ²Academic Information Systems, UT Southwestern Medical Center, Dallas, TX, ³Medicine, Penn State MS Hershey Medical Center, Hershey, PA
Background/Purpose: The electronic medical record (EMR) is increasingly used as a primary source of retrospective research data from large 'virtual cohorts' of patients. The accuracy…
Abstract Number: 1570 • 2013 ACR/ARHP Annual Meeting
Maintenance Therapy With Taclorimus and Mizoribine Pulse In SLE
Hiroshi Kajiyama¹, Daisuke Ikuma¹, Muneo Ota², Yuki Shimada¹, Kazuhiro Yokota³, Yasuto Araki¹, Kojiro Sato¹, Yu F. Asanuma¹, Yuji Akiyama¹ and Toshihide Mimura⁴, ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ²Saitama Medical University, Saitama, Japan, ³Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: It was reported in 2008 that multitarget therapy, consisting of taclorimus (TAC), mycophenolate mofetil (MMF) and glucocorticoid, is effictive and safe in induction therapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].